| Name | Title | Contact Details |
|---|---|---|
Monette Ablan |
Senior Director, Enterprise Compensation | Profile |
Rosalie Filling |
Vice President, Global Head R&D Operations | Profile |
Henry Wolfe |
Vice President, Biologics Research & Development | Profile |
James Tursi |
Executive Vice President, Global Research and Development | Profile |
Matthew Davis |
Chief Scientific Officer, SVP Global Branded R&D | Profile |
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.
Throughout our 100 plus year history, Hartig Drug has played a key role in progressive retail practices. Did you know that Hartig Drug opened the first self-service drug store in Iowa and was one of the first pharmacies to employ female pharmacists and store managers? The principles upon which A.J. Hartig founded the company, offering the best product selection and providing fanatical service to his customers, are the corner stone of our company culture today. Hartig Drug has expanded its product offerings in retail and pharmacy and has grown via the addition of many stores throughout the years. Our drug stores and pharmacies are located in communities in Northeast Iowa, Northwest Illinois, and Southwest Wisconsin. Hartig Drug operates retail stores, long-term care pharmacies, and Finley Hartig Homecare, a durable medical equipment company. Additionally, we provide pharmacy services to and for several community critical access hospitals and operate MedOne Healthcare, a pharmacy benefit management company that offers customized prescription benefit plans to businesses, prescription discount programs, prescription mail order service and specialty pharmacy services. Hartig Drug remains active in the communities in which we serve. Our employees, live, work and play in the communities in which we operate. This connection to the community is what drives us every day to provide the best possible service and products to our patients and customers. They are our neighbors. At Hartig Drug, we cherish the faith and trust patients and customers have placed in our brand and the way the Hartig name has become synonymous with value, caring associates and a wide selection of quality merchandise.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
EpiCeram® Controlled Release Skin Barrier Emulsion is a leading prescription product that has the ability to help repair and heal the skin barrier through a unique mode-of-action different from other medications and eczema treatments. Only EpiCeram® co...